X0204 3 2011-11-15 0 0001466301 Clovis Oncology, Inc. CLVS 0001456590 Versant Venture Capital IV, L.P. 3000 SAND HILL ROAD BUILDING FOUR, SUITE 210 MENLO PARK CA 94025 0 0 1 0 0001456591 Versant Side Fund IV, L.P. 3000 SAND HILL ROAD BUILDING FOUR, SUITE 210 MENLO PARK CA 94025 0 0 1 0 0001456589 Versant Ventures IV, LLC 3000 SAND HILL ROAD BUILDING FOUR, SUITE 210 MENLO PARK CA 94025 0 0 1 0 Series A-1 Convertible Preferred Stock 0.00 Common Stock 295404 I See Footnote Series A-1 Convertible Preferred Stock 0.00 Common Stock 1861 I See Footnote Series A-2 Convertible Preferred Stock 0.00 Common Stock 295404 I See Footnote Series A-2 Convertible Preferred Stock 0.00 Common Stock 1861 I See Footnote Series B Convertible Preferred Stock 0.00 Common Stock 639403 I See Footnote Series B Convertible Preferred Stock 0.00 Common Stock 4027 I See Footnote Convertible Promissory Note 3396603.32 Common Stock 267755 I See Footnote Convertible Promissory Note 21396.68 Common Stock 1686 I See Footnote Each share of Common Stock, Series A-1, Series A-2 and Series B Convertible Preferred Stock will automatically convert on a 1-for-1 basis into common stock upon the consummation of the Issuer's initial public offering. The securities are immediately convertible. The expiration date is not relevant to the conversion of these securities. The shares are held by Versant Venture Capital IV, L.P. ("Versant IV"). In their capacity as managing members of Versant Ventures IV, LLC which is the general partner of each Versant IV, Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Kirk G. Nielsen share voting and investment authority over the shares held by the Versant IV and may be deemed to beneficially own the shares. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Kirk G. Nielsen disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein. The shares are held by Versant Side Fund IV, L.P. ("Versant Side"). In their capacity as managing members of Versant Ventures IV, LLC which is the general partner of each Versant Side, Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Kirk G. Nielsen share voting and investment authority over the shares held by the Versant Side and may be deemed to beneficially own the shares. Each of Brian G. Atwood, Ross A. Jaffe, M.D., Camille D. Samuels, Kevin J. Wasserstein, Samuel D. Colella, Rebecca B. Robertson, Bradley J. Bolzon, Ph.D., William J. Link, Ph.D., Charles M. Warden, Robin L. Praeger and Kirk G. Nielsen disclaim beneficial ownership of these shares except to the extent of his or her pecuniary interest therein. The outstanding principal amount and all accrued and unpaid interest thereon will convert into shares of common stock at a price per share equal to the initial public offering price upon consummation of the Issuer's initial public offering. VERSANT VENTURE CAPITAL IV, L.P. By: Versant Ventures IV, LLC Its: General Partner By: /s/ Brian G. Atwood Brian G. Atwood, Managing Director 2011-11-15 VERSANT SIDE FUND IV, L.P. By: Versant Ventures IV, LLC Its: General Partner By: /s/ Brian G. Atwood Brian G. Atwood, Managing Director 2011-11-15 VERSANT VENTURES IV, LLC By: /s/ Brian G. Atwood Brian G. Atwood, Managing Director 2011-11-15